BioSpace News Archive

Cabaletta Bio, Inc. (Nasdaq: CABA) today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 8:20 a.m. ET in Miami, FL.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Seelos Therapeutics, Inc. announced that it has priced its underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock and accompanying common warrants to purchase up to 4,204,546 shares of its common stock.

Alpha Cognition Inc. reported financial results for the third quarter and nine months ended September 30, 2023, and provided a corporate update.

Cyclacel Pharmaceuticals, Inc. announced that it received a notice of non-compliance from Nasdaq Stock Market LLC on November 21, 2023 stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the quarter ended September 30, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that it will be presenting new Phase 1b/2 clinical data of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib, a Poster Spotlight Session on Phase 2 clinical data of palazestrant in combination with palbociclib, and a trial-in-progress poster for the OPERA-01 monotherapy Phase 3 pivotal trial at the upcoming San Antonio Breast Cancer Symposium.

AIM ImmunoTech Inc. announced that the Company will convene its upcoming 2023 Annual Meeting of Stockholders as planned on December 1, 2023, and will then adjourn proceedings, without conducting any other business, until December 29, 2023.

Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, announces that data supporting the use of its platform to determine HER2 status in patients with metastatic breast cancer will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Biovica International Continued sales growth and several commercial agreements signed.